Quarterly Other Accumulated Expenses rose 25.88% to $13.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.1 million through Dec 2025, up 25.88% year-over-year, with the annual reading at $13.1 million for FY2025, 25.88% up from the prior year.
Other Accumulated Expenses hit $13.1 million in Q4 2025 for CRISPR Therapeutics AG, up from $604000.0 in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $13.1 million in Q4 2025 to a low of $20000.0 in Q4 2022.
Historically, Other Accumulated Expenses has averaged $1.9 million across 5 years, with a median of $489000.0 in 2024.
Biggest five-year swings in Other Accumulated Expenses: plummeted 97.63% in 2021 and later surged 25605.0% in 2023.
Year by year, Other Accumulated Expenses stood at $171000.0 in 2021, then tumbled by 88.3% to $20000.0 in 2022, then soared by 25605.0% to $5.1 million in 2023, then skyrocketed by 102.63% to $10.4 million in 2024, then rose by 25.88% to $13.1 million in 2025.
Business Quant data shows Other Accumulated Expenses for CRSP at $13.1 million in Q4 2025, $604000.0 in Q2 2025, and $461000.0 in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value